Who do I have to suck for some eloralintide

Status
Not open for further replies.

TopzyTirzy

GLP-1 Novice 🚫No Source Discussion🚫
Imported Novice
Member Since
Sep 9, 2025
Posts
23
Likes Received
107
Location
United States
I don’t have any experience, but I have a great attitude and really want some eloralintide. I could really make some chinese peptide manufacturers weekend nice if given the chance.

Sema and tirz both give me anhedonia, and this chest anxiety/tachycardia, reta doesnt, but i want more appetite suppressant. Just ordered cagri, but I want the new fancy amylin receptor agonist😭, I also think it has a heart rate lowering effect which would be nice.

Why do these random biotech phds in china take so long in getting me illicit cutting edge pharmaceuticals when IIIII WANTTTT THEM NOW
 
TopzyTirzy said:
I don’t have any experience, but I have a great attitude and really want some eloralintide. I could really make some chinese peptide manufacturers weekend nice if given the chance.

Sema and tirz both give me anhedonia, and this chest anxiety/tachycardia, reta doesnt, but i want more appetite suppressant. Just ordered cagri, but I want the new fancy amylin receptor agonist😭, I also think it has a heart rate lowering effect which would be nice.

Why do these random biotech phds in china take so long in getting me illicit cutting edge pharmaceuticals when IIIII WANTTTT THEM NOW
Really? Have to suck?
 
miss-sanne said:
Eloralintide is not even in phase 1 trial yet ?
Actually, the Phase II results were released during Obesity Week. That was the cause for the excitement. Phase III is supposed to start before the end of 2025. Reta has been a grey market staple since it released its Phase II data, so I don't see why the grey market wouldn't produce it based on such good Phase II results.

----------------------------------------------------------------------------------------------

Eloralintide Phase II results ​[archived internal link]
According to the study authors, 263 participants (mean age 49.0 years, mean bodyweight 109.1 kg, BMI 39.1 kg/m², 78% female, 78% White) were randomized to receive either eloralintide (1 mg, n=28; 3 mg, n=24; 6 mg, n=28; 9 mg, n=54; 6-9 mg, n=24; 3-9 mg, n=52) or placebo (n=53) between Feb. 5, 2024, and Aug. 14, 2025.2

Emerging data from the Phase II trial show:

After 48 weeks, mean percent change in bodyweight from baseline (efficacy estimand) ranged from -9% at 1 mg to -20% at 9 mg, compared with -0.4% in the placebo group.

The greatest weight reductions were observed in the 9 mg and 6-9 mg cohorts (-20% each; 95% CI: -22.7 to -17.5 and -22.7 to -17.0, respectively).

“Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment,” the authors wrote.
 
YoYoFat said:
Yeah, I’m surprised we’re not seeing it from vendors already. That recipe must be under lock and key, or too expensive to reproduce.
I think they just published the details of the sequence. From what I read it isn't that complicated (not that I am a peptide production expert).
 
Ok, sent the sequence to Chatgpt. I won't bore everyone with the pages of details, but here is the conclusion:

----------------------------------------------------------------------------------------------------

🧪 Where eloralintide sits in difficulty relative to tirzepatide & retatrutide ​[archived internal link]

Feature Tirzepatide Retatrutide Eloralintide Difficulty Length ~39 aa ~40 aa ~40 aa Same Lipid tail γGlu–γGlu–C20 γGlu–γGlu–C20 γGlu–γGlu–C20 Same Cys handling None None Two Cys w/ thioether bridge Eloralintide harder Non-standard residues Yes Yes Yes Same GMP / large scale Yes Yes Depends on vendor Vendor-specific

Conclusion:

The only added complexity is the thioether bridge. Everything else is squarely in the wheelhouse of a tirzepatide vendor.
 
m100568 said:
Actually, the Phase II results were released during Obesity Week. That was the cause for the excitement. Phase III is supposed to start before the end of 2025. Reta has been a grey market staple since it released its Phase II data, so I don't see why the grey market wouldn't produce it based on such good Phase II results.

----------------------------------------------------------------------------------------------

Eloralintide Phase II results ​
According to the study authors, 263 participants (mean age 49.0 years, mean bodyweight 109.1 kg, BMI 39.1 kg/m², 78% female, 78% White) were randomized to receive either eloralintide (1 mg, n=28; 3 mg, n=24; 6 mg, n=28; 9 mg, n=54; 6-9 mg, n=24; 3-9 mg, n=52) or placebo (n=53) between Feb. 5, 2024, and Aug. 14, 2025.2

Emerging data from the Phase II trial show:

After 48 weeks, mean percent change in bodyweight from baseline (efficacy estimand) ranged from -9% at 1 mg to -20% at 9 mg, compared with -0.4% in the placebo group.

The greatest weight reductions were observed in the 9 mg and 6-9 mg cohorts (-20% each; 95% CI: -22.7 to -17.5 and -22.7 to -17.0, respectively).

“Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment,” the authors wrote.
thanks, didn't know !
 
m100568 said:
Ok, sent the sequence to Chatgpt. I won't bore everyone with the pages of details, but here is the conclusion:

----------------------------------------------------------------------------------------------------

🧪 Where eloralintide sits in difficulty relative to tirzepatide & retatrutide ​

Feature Tirzepatide Retatrutide Eloralintide Difficulty Length ~39 aa ~40 aa ~40 aa Same Lipid tail γGlu–γGlu–C20 γGlu–γGlu–C20 γGlu–γGlu–C20 Same Cys handling None None Two Cys w/ thioether bridge Eloralintide harder Non-standard residues Yes Yes Yes Same GMP / large scale Yes Yes Depends on vendor Vendor-specific

Conclusion:

The only added complexity is the thioether bridge. Everything else is squarely in the wheelhouse of a tirzepatide vendor.
What’s “cys handling”?
 
YoYoFat said:
What’s “cys handling”?
isn't it some chemical stuff, a konfiguration, - the peptides 'blueprint' ?

Because of the konfiguration, it's more difficult to make ?

Cys may be 'cystein', the amino acid ??

I'm not a chemist, though ;-)
 
TopzyTirzy said:
Sema and tirz both give me anhedonia, and this chest anxiety/tachycardia, reta doesnt, but i want more appetite suppressant. Just ordered cagri, but I want the new fancy amylin receptor agonist😭, I also think it has a heart rate lowering effect which would be nice.

Why do these random biotech phds in china take so long in getting me illicit cutting edge pharmaceuticals when IIIII WANTTTT THEM NOW
What dose of reta are you on? I always wait until I'm at the maximum dose of a GLP before offering services.
 
miss-sanne said:
Why don’t you just use the cagri you ordered ? I love it, 0,25 mg is so good.

Eloralintide is not even in phase 1 trial yet ?

Why would you choose that ?
Eloranlintide has completed at least one phase 2 trial. Billings, et al. (pre-publication, 2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity - a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, doi-10.1016/S0140-6736(25)02155-5 . At least one other phase two trial is ongoing. Hsia, et al (Obesity Week 2025). Poster - Eloralintide Phase 2 Study in Adult Participants With Overweight or Obesity - Design and Study Population . Yes, elorantlintide is behnd reta in development and far behind tirz. Still much work has been done on developing it.
 
keangkong said:
Eloranlintide has completed at least one phase 2 trial. Billings, et al. (pre-publication, 2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity - a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, doi-10.1016/S0140-6736(25)02155-5 . At least one other phase two trial is ongoing. Hsia, et al (Obesity Week 2025). Poster - Eloralintide Phase 2 Study in Adult Participants With Overweight or Obesity - Design and Study Population . Yes, elorantlintide is behnd reta in development and far behind tirz. Still much work has been done on developing it.
Thanks yes I realized that now, thanks for this !

It seems, it’s much more weight loss than cagri. (Why the pairing of sema and cagri).
 
m100568 said:
Ok, sent the sequence to Chatgpt. I won't bore everyone with the pages of details, but here is the conclusion:

----------------------------------------------------------------------------------------------------

🧪 Where eloralintide sits in difficulty relative to tirzepatide & retatrutide ​

Feature Tirzepatide Retatrutide Eloralintide Difficulty Length ~39 aa ~40 aa ~40 aa Same Lipid tail γGlu–γGlu–C20 γGlu–γGlu–C20 γGlu–γGlu–C20 Same Cys handling None None Two Cys w/ thioether bridge Eloralintide harder Non-standard residues Yes Yes Yes Same GMP / large scale Yes Yes Depends on vendor Vendor-specific

Conclusion:

The only added complexity is the thioether bridge. Everything else is squarely in the wheelhouse of a tirzepatide vendor.
Given how China has run away with Eli Lilly's IP on Tirz and Reta, EL's patent attorneys will have thought long and hard on how to disclose Elora details to the patent office. You cannot legally withhold technical details in a patent app. However, you can strategically craft your disclosure so that others cannot easily reproduce the peptide. They didn't do that with Tirz (fool me once) and again not with Reta (fool me twice) and so, what is our collective guess as to what they will do with Elora?

They can do this by claiming families of sequences, rather than specific. Example: position X contains a noncanonical α-methyl-Leu. Another way is to incorporate a key manufacturing step that they never have to disclose. Example: resin chemistry or buffer conditions. Another tactic is to disclose one workable embodiment (recipe) but not the best one that works.

I used to be a chemist in the beverage industry and own one chemistry patent. I've worked with patent attorneys. So this is all an educated guess. More like a worry.

Our Chinese grey friends may be real busy splish-splashing Elora in their bathtubs, but what the heck are they making? May be Elora spot on. May be something very Elora-like with off-target effects. When the first grey Elora shipment drops, my thinking will be ' You first! '
 
Dogmandu said:
Given how China has run away with Eli Lilly's IP on Tirz and Reta, EL's patent attorneys will have thought long and hard on how to disclose Elora details to the patent office. You cannot legally withhold technical details in a patent app. However, you can strategically craft your disclosure so that others cannot easily reproduce the peptide. They didn't do that with Tirz (fool me once) and again not with Reta (fool me twice) and so what is our collective guess as to what they will do with Elora?

They can do this by claiming families of sequences. Example: position X contains a noncanonical α-methyl-Leu. Another way is to incorporate a key manufacturing that they never have to disclose. Example: resin chemistry or buffer conditions. Another tactic is to disclose one workable embodiment (recipe) but not the good one that works.

I used to be a chemist in the beverage industry and own one chemistry patent. I've worked with patent attorneys. So this is all an educated guess. More like a worry.

Our Chinese grey friends may be real busy splish-splashing Elora in their bathtubs, but what the heck are they making? May be Elora spot on. May be something close. When the first grey Elora shipment drops, my thinking will be 'You first!'
Thank you for this excellent response full of actual first hand knowledge! When do you want to be sucked?
 
Status
Not open for further replies.

Trending content

Members online

No members online now.

Forum statistics

Threads
3,903
Messages
85,862
Members
4
Latest member
david
Back
Top